Frank, age 58, professor, is a symptomatic patient with moderate COPD not yet on maintenance therapy and has had no exacerbations in the last 12 months.
Shortness of breath
Regular rescue medication use
Pulling away from normal activities
“My doctor knows me, and she knows that not every patient with COPD should be treated the same. That’s why we started with ANORO.”
For the last 3 years, the GOLD report has supported starting symptomatic patients on a LAMA/LABA
Continues to emphasize the role of LAMA/
Does not include ICS/LABA as initial treatment in many patients
ANORO was studied in patients with moderate or worse COPD.
*Defined as statistically significant improvements in lung function relative to its individual components and placebo in a 24-week, randomized, double-blind study in patients with COPD (N=1532).